Janus Henderson Group PLC Sells 22,527 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Janus Henderson Group PLC trimmed its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 7.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 301,490 shares of the biotechnology company's stock after selling 22,527 shares during the quarter. Janus Henderson Group PLC owned approximately 0.29% of Corcept Therapeutics worth $15,191,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in CORT. Kestra Investment Management LLC bought a new position in shares of Corcept Therapeutics during the 4th quarter worth approximately $27,000. Canada Pension Plan Investment Board acquired a new stake in Corcept Therapeutics during the 4th quarter valued at $40,000. National Bank of Canada FI bought a new position in Corcept Therapeutics during the fourth quarter worth $42,000. USA Financial Formulas acquired a new position in shares of Corcept Therapeutics in the fourth quarter valued at $54,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Corcept Therapeutics in the fourth quarter valued at $58,000. Institutional investors and hedge funds own 93.61% of the company's stock.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $70.22, for a total transaction of $154,484.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Joseph K. Belanoff sold 2,924 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $60.91, for a total value of $178,100.84. Following the sale, the chief executive officer now directly owns 3,019,411 shares in the company, valued at $183,912,324.01. This trade represents a 0.10% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 296,352 shares of company stock worth $24,908,205. Corporate insiders own 20.80% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on CORT shares. Canaccord Genuity Group increased their price target on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Truist Financial set a $135.00 target price on shares of Corcept Therapeutics in a report on Tuesday, May 6th. Wall Street Zen downgraded Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, May 14th. HC Wainwright decreased their price target on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Finally, Piper Sandler upped their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a report on Thursday, April 3rd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $138.25.

Corcept Therapeutics Trading Down 1.3%

Corcept Therapeutics stock traded down $1.02 during trading hours on Thursday, reaching $74.79. 161,662 shares of the company's stock were exchanged, compared to its average volume of 1,121,671. The firm has a market capitalization of $7.93 billion, a PE ratio of 59.32 and a beta of 0.22. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The firm's 50 day simple moving average is $69.78 and its 200 day simple moving average is $62.20. Corcept Therapeutics Incorporated has a twelve month low of $27.30 and a twelve month high of $117.33.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its earnings results on Monday, May 5th. The biotechnology company reported $0.17 EPS for the quarter, meeting analysts' consensus estimates of $0.17. The business had revenue of $157.21 million during the quarter, compared to analyst estimates of $177.93 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm's revenue was up 7.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.25 EPS. Research analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.